Aduro Biotech Sweden

GPTKB entity

Statements (61)
Predicate Object
gptkbp:instance_of gptkb:Company
gptkbp:bfsLayer 5
gptkbp:bfsParent gptkb:Aduro_Biotech,_Inc.
gptkbp:clinical_trial Phase 1 trials
Phase 2 trials
gptkbp:collaborated_with research institutions
biotech firms
gptkbp:collaborates_with academic institutions
gptkbp:collaborations universities
clinical centers
gptkbp:community_engagement gptkb:hospital
patient advocacy groups
gptkbp:develops cancer treatments
gptkbp:employs gptkb:physicist
gptkbp:focuses_on gptkb:vaccine
gptkb:drug
personalized medicine
cancer immunotherapy
novel therapies
gptkbp:founded gptkb:2014
gptkbp:has_mission improve cancer treatment
gptkbp:has_product ADU-741
ADU-CL-24
gptkbp:has_property patents
trademarks
gptkbp:has_website adurobiotech.com
gptkbp:headquarters gptkb:Sweden
https://www.w3.org/2000/01/rdf-schema#label Aduro Biotech Sweden
gptkbp:is_active_in European market
global market
gptkbp:is_engaged_in public-private partnerships
clinical development
gptkbp:is_involved_in clinical trials
biomedical research
therapeutic development
research collaborations
gptkbp:is_known_for innovative therapies
patient-centric approach
gptkbp:is_part_of biopharmaceutical industry
gptkbp:is_recognized_by industry awards
research publications
gptkbp:is_supported_by gptkb:Company
grants
government funding
philanthropic donations
gptkbp:leadership gptkb:CEO
scientific advisory board
gptkbp:located_in gptkb:Lund
gptkbp:part_of Aduro Biotech Inc.
gptkbp:participates_in clinical research
gptkbp:partnerships pharmaceutical companies
gptkbp:receives_funding_from gptkb:Company
gptkbp:regulatory_compliance gptkb:FDA
gptkb:EMA
gptkbp:research_focus T-cell activation
immune response
gptkbp:strategic_importance enhance research capabilities
expand product pipeline
gptkbp:technology genetic engineering
biologics
gptkbp:vision transform cancer care